US health technology assessor the Institute for Clinical and Economic Review (ICER) yesterday posted its revised Evidence Report assessing the comparative clinical effectiveness and value of ...

This was the stock's fourth consecutive day of gains.

On Vertex's Q4 earnings call, investors will focus on management's comments about launch preparation for Alyftrek (vanza ...

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Vertex (VRTX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the ...

The S&P 500 index trades at a forward price/earnings ratio of 21.9. The U.S. large-cap benchmark stock index is weighted by market capitalization. The index's current forward P/E valuation is 18% ...

Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 20 years ago, it would be worth $4,232.95 today based on a ...

Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a ...

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...

Financial giants have made a conspicuous bearish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex ...